Xcout Intel
Repertoire Immune Medicines competitors & alternatives
The 12 closest competitors and alternatives to Repertoire Immune Medicines among biotech companies — ranked by similarity to what Repertoire Immune Medicines actually does, not by market-cap band.
Subscribe to see Repertoire Immune Medicines’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Repertoire Immune Medicines
Repertoire Immune Medicines is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts. The firm works to unlock and direct the power of the human immune system to develop novel therapeutics and medicines.
Repertoire Immune Medicines at a glance
Repertoire Immune Medicines is a biotech company headquartered in United States. Xcout tracks 18 named people at Repertoire Immune Medicines, including Torben Straight Nissen (Chief Executive Officer). Xcout recorded 1 job posting from Repertoire Immune Medicines in the last 90 days.
Repertoire Immune Medicines leadership
- Torben Straight NissenChief Executive Officer
- Anthony CoylePresident, Research and Development
- Jan KisielowChief Scientific Officer, Repertoire Immune Medicines (Switzerland) Ltd.
- John DelyaniChief Business Officer
- Robert AndtbackaChief Medical Officer
- JC Gutierrez-RamosChief Science Officer, Danaher Corporation
12 more named people on record for Repertoire Immune Medicines, with roles, board committees and tenure — see the full roster →
Hiring at Repertoire Immune Medicines
Xcout recorded 1 job posting from Repertoire Immune Medicines in the last 90 days, from a hiring record Xcout has kept since August 2026.
The weekly hiring trend, the roles and locations behind it — see Repertoire Immune Medicines's hiring signals →
Top 12 Repertoire Immune Medicines competitors
Ranked by semantic similarity — how close each company is to Repertoire Immune Medicines by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
CREATE Medicines is a clinical-stage biotechnology company located in Cambridge, Massachusetts, pioneering in vivo immune programming with RNA.
Similar biotech company
HiFiBio Therapeutics is a clinical-stage immune modulation biotechnology company headquartered in Cambridge, Massachusetts. The company focuses on discovering and developing novel precision antibody therapeutics for immunology and oncology applications.
Biotechnology
Checkmate Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on developing proprietary technology to stimulate the immune system to combat cancer.
Biotechnology
Stipple Bio, Inc. is a private biotechnology company headquartered in Cambridge, Massachusetts, United States, focused on harnessing epitope-level precision in therapeutics.
Biotechnology
Ankyra Therapeutics is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts. The company develops localized immune-mediated therapies for the treatment of cancer.
Biotechnology
Immunitas Therapeutics, Inc. is a US-based biotechnology company established in 2019 and headquartered in Waltham, Massachusetts. The company focuses on pioneering novel therapeutic treatments in immunology and oncology.
Biotechnology
BIND Therapeutics, Inc. is a clinical-stage nanomedicine company headquartered in Cambridge, Massachusetts. The company specializes in developing targeted and programmable therapeutics using its proprietary platform to treat various diseases.
Biotechnology
Sift Biosciences is a privately held biotechnology company founded in 2024 and headquartered in San Carlos, California. The company is focused on harnessing pre-existing hidden immunity.
Biotechnology
Red Queen Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on antiviral therapeutics, with its headquarters located in Cambridge, Massachusetts.
Similar biotech company
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
Biotechnology
Affinivax, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, that pioneered a novel class of multiplex vaccine technologies.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Repertoire Immune Medicines and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Repertoire Immune Medicinesand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →